Saturday, 22 July 2017

Avacen’s new device secures Health Canada approval

26 May 2017 | News

The new CE-marked device employs the firm’s new treatment method in which heat is non-invasively and safely induced into the circulatory system.

US-based pain relief solutions provider Avacen Medical has secured medical device licence approval from Health Canada for its new pain treatment device, Avacen 100.

The new CE-marked device employs the firm’s new treatment method in which heat is non-invasively and safely induced into the circulatory system.

The infusion of heat leads to muscular relaxation and increase of microcirculation in the body. The firm intends to further seek Health Canada’s approval to extend the use of Avacen 100 for the treatment of fibromyalgia, which is a chronic widespread pain.

In addition to Health Canada, the US Food and Drug Administration (FDA), India FDA and European Union (EU) approved the device for temporary relief of minor muscle and joint pain, stiffness, muscle spasms, joint pain related to arthritis, as well as minor strains and sprains. They also approved the device for the temporary increase of local circulation and muscular relaxation.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is digitalisation a global challenge for Indian pharma companies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls